Ensysce Biosciences, Inc.
ENSCNASDAQHealthcare● Active
$0.25
$-0.00(-0.43%)
Market Cap$2347288
P/E Ratio—
52W High$2.75
52W Low$0.23
Ensysce Biosciences, Inc. (ENSC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ENSC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.52
Est. -$0.73 · +28.8%
Revenue
$0.00B
Est. $0.00B · -47.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
ENSC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.50 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.73 | -$0.52 | +28.8% | $0.00B | $0.00B | -47.4% |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$1.26 | -$0.75 | +40.5% | $0.00B | $0.00B | +277.8% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.85 | -$1.29 | -51.8% | $0.00B | $0.00B | -29.6% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$1.02 | -$0.79 | +22.6% | $0.00B | $0.00B | -2.0% |
| ▲ Q2 FY2025 | May 13, 2025 | -$3.02 | -$1.39 | +54.0% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 10, 2025 | -$2.74 | -$2.90 | -5.8% | $0.00B | $0.00B | +432.2% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$4.50 | $1.05 | +123.3% | $0.00B | $0.00B | +1295.5% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.50
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.52
EPS Est.
-$0.73
EPS Surpr.
+28.8%
Revenue
$0.00B
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.75
EPS Est.
-$1.26
EPS Surpr.
+40.5%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$1.29
EPS Est.
-$0.85
EPS Surpr.
-51.8%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.79
EPS Est.
-$1.02
EPS Surpr.
+22.6%
Revenue
$0.00B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$1.39
EPS Est.
-$3.02
EPS Surpr.
+54.0%
Revenue
$0.00B
Q1 FY2025
Mar 10, 2025Miss
EPS Actual
-$2.90
EPS Est.
-$2.74
EPS Surpr.
-5.8%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
$1.05
EPS Est.
-$4.50
EPS Surpr.
+123.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Q3 FY2026 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q2 FY2026 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q1 FY2026 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q4 FY2025 | $-1.26 | $-1.26 | $-1.26 | 1 |
| Q3 FY2025 | $-0.90 | $-0.82 | $-0.74 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +28.8% | $0.28 | $0.28 | +1.05% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +40.5% | $0.53 | $0.51 | -2.56% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -51.8% | $2.07 | $2.06 | -0.48% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +22.6% | $2.09 | $2.15 | +2.87% |
| ▲ Q2 FY2025 | May 13, 2025 | +54.0% | $2.19 | $2.07 | -5.48% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -5.8% | $5.02 | $4.83 | -3.78% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +123.3% | $10.37 | $10.12 | -2.41% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +43.6% | $6.14 | $5.85 | -4.72% |
Q2 FY2026+1.05%
Report Date
May 15, 2026
EPS Beat/Miss
+28.8%
Price Before
$0.28
Price After
$0.28
Q1 FY2026-2.56%
Report Date
Mar 30, 2026
EPS Beat/Miss
+40.5%
Price Before
$0.53
Price After
$0.51
Q4 FY2025-0.48%
Report Date
Nov 14, 2025
EPS Beat/Miss
-51.8%
Price Before
$2.07
Price After
$2.06
Q3 FY2025+2.87%
Report Date
Aug 13, 2025
EPS Beat/Miss
+22.6%
Price Before
$2.09
Price After
$2.15
Q2 FY2025-5.48%
Report Date
May 13, 2025
EPS Beat/Miss
+54.0%
Price Before
$2.19
Price After
$2.07
Q1 FY2025-3.78%
Report Date
Mar 10, 2025
EPS Beat/Miss
-5.8%
Price Before
$5.02
Price After
$4.83
Q4 FY2024-2.41%
Report Date
Nov 12, 2024
EPS Beat/Miss
+123.3%
Price Before
$10.37
Price After
$10.12
Q3 FY2024-4.72%
Report Date
Aug 14, 2024
EPS Beat/Miss
+43.6%
Price Before
$6.14
Price After
$5.85
Avg Beat Reaction-1.88%
Avg Miss Reaction-2.13%
Beat Rate6 / 8 quarters
Largest Move-5.48% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ENSC ends December
Ensysce Biosciences, Inc. (ENSC) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.52 — beating the analyst consensus of $-0.73 by +28.8%. ENSC has beaten EPS estimates for 2 consecutive quarters. The next ENSC earnings date is expected around September 1, 2026.
Each quarter, investors track ENSC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ENSC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ENSC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ENSC earnings · 5 questionsEnsysce Biosciences, Inc.'s next earnings report is expected around September 1, 2026. ENSC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ENSC historically reports after market close (AMC).
ENSC earnings datewhen is ENSC earningsENSC next earnings datewhen does ENSC report earningsENSC earnings calendar
▸ Source: FMP · Ensysce Biosciences, Inc. SEC filings · US GAAP · Ensysce Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026